chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Vomiting; Nausea; Stomach Pain; Dizziness; A lot of headache that still continues; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (A lot of headache that still continues), DIZZINESS (Dizziness), VOMITING (Vomiting), NAUSEA (Nausea) and ABDOMINAL PAIN UPPER (Stomach Pain) in a 32-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 033C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 25-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage form. On 25-May-2021, the patient experienced HEADACHE (A lot of headache that still continues). On 29-May-2021, the patient experienced DIZZINESS (Dizziness). On 30-May-2021, the patient experienced VOMITING (Vomiting), NAUSEA (Nausea) and ABDOMINAL PAIN UPPER (Stomach Pain). The patient was treated with CHLORPHENAMINE MALEATE, PARACETAMOL, PHENYLPROPANOLAMINE HYDROCHLORIDE (CORICIDIN D [CHLORPHENAMINE MALEATE;PARACETAMOL;PHENYLPROPANOLAMINE HYDROCHLORIDE]) at an unspecified dose and frequency and ACETAMINOPHEN for Headache, at an unspecified dose and frequency. At the time of the report, HEADACHE (A lot of headache that still continues), DIZZINESS (Dizziness), VOMITING (Vomiting), NAUSEA (Nausea) and ABDOMINAL PAIN UPPER (Stomach Pain) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route), the reporter did not provide any causality assessments.   Med Info Agent:  Patient stated she had first dose of Moderna vaccine on Tuesday 25 May 2021 and since Tuesday night started to have a lot of headache that continues. On Saturday she started to feel dizzy and this continues, and on Sunday started to vomit and have nausea and stomach pain which continues. Says that her headache doesn't stop with anything. She already had Coricidin and Acetaminophen and pills for migraine each five or six hours but doesn't take out her headache.  Stated she doesn't have concomitant medications. Expiration date of vaccine is unknown.  Consent for Safety to follow up with patient, preferred method of contact by phone. Patient stated she doesn't have a doctor to provide contact for Safety to follow up.
7/18/2006 sore throat x 4 days, weakness in both legs. Dx: Guillain Barre syndrome. 7/19/06 progressive weakness in legs and hands. 7/19/06 Hospital; 8/5/06 discharged to extended care.  08/23/06-received from Dr:  office note 7/18/06: Returned to office on this date after Tdap on 7/7/06:  C/O sore throat for 4 days weakness both legs.  Quick Strep no results documented.  PE: patellar to ankles DTR absent        motion: leg extension, toe extension and plantar flexion all seen to be WNL        able to walk on toes without difficulty.  Impression: acute pharyngitis with weakness in legs, consider Guillain Barre although no objective signs at this time.   DC Summary from DOS: 7/19-8/5/06  Reason for admission: weakness  Chief Complaint: acute onset of progressive weakness. On [[name]] of admissions woke up and noted tingling and weakness in his hands, dropped bar of soap several time while showering. Continued to have weakness in lower extremities.   Received DPT booster 7/7/06 and also exposed to gastroenteritis.  DC DX: Guillain Barré syndrome  DC to extended care facility. Hospital Course: difficulty walking and raising his arms (right worse than left) above his head due to weakness, numbness in toes and finger tips as well as "tightness" in calves and thighs. Denies SOB, recent tick bits, bowel or bladder incontinence. No headache, loss of vision, blurred vision, diplopia, dysarthria, dysphagia, lightheadedness, vertigo, tinnitus or hearing difficulty or difficulties producing or comprehending speech. Denied fever, chills, night sweats, recent weight loss or gain, cough, chest pain or tightness, palpitations, nausea, vomiting, diarrhea, constipation or abdominal pain, change in bowel or bladder habits, dysuria, arthralgias or myalgias.  PE: WNL. Extremities: No C/C/E bilaterally, 2+ radial, DP and PT pulses bilaterally.  Neurologic: WNL: thigh adduction and abduction 5/5/ bilaterally. Foot inversion and eversion 4/5/ bilaterally, neck extensors and flexors 5/5 bilaterally.  Sensory: diminished JPS to but not large amplitude movements at the great toes bilaterally. Loss of vibratory sense to the level of medial malleoli bilaterally, stocking and glove distribution diminution of pinprick and cold sensation bilaterally.  Coordination: no intention tremor, dysdiadochokinesia noted. No dysmetria on FNF bilaterally (with elbow supported).   Plantar response was mute bilaterally.  Gait: slowed initiation, wide based essentially he locked the kneeds and waddled, appeared very unsteady.  Exam on DC:   DTRs absent, Sens: LT L>R in feet, equal o/w  Coor-FNF dysmetric but in proportion to weakness  CSF: protein 69, glucose 60, WBC 1 RBC 2, Poly 18, Lymphs 59, Monos 24.  HX, exam findings lab results consistent with a diagnosis of Guillain-Barre Syndrome, inciting source was nto found, with mycoplasma IgM negative, Lyme negative, C jejuni IgG negative.  DC to rehabilitation facility. Per information received from the annual follow up, he still has muscle weakness but improving.   Per 60 day follow up: 11-3-06 continues rehab. 3x/ week continues fatigue, can walk up and down stairs. This patient has a physician visit scheduled for February.
rash and redness at injection site; rash and redness at injection site; This is a spontaneous report from a contactable consumer. A 67-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot number was not reported), dose 2 via an unspecified route of administration on 05Mar2021 (at the age of 67years) as 2ND DOSE, SINGLE for Covid-19 immunization. The patient received the first dose of BNT162B2 in Feb2021 (at the age of 67years) for Covid-19 immunization. The patient was not pregnant at the time of vaccination. The patient's medical history and concomitant medications were not reported. It was unknown if the patient received any other vaccines within 4 weeks prior to the COVID vaccine. It was reported that the patient received the 2nd dose of vaccine on Friday, 05Mar2021, and developed rash and redness at injection site about one day later (06Mar2021), which was treated with antibiotic (oral). The events resulted in Doctor or other healthcare professional office/clinic visit. The outcome of events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot been obtained.
Approx. 3-5 min. after vac. c/o severe S/A positive N/V progressing to sleepiness, EPIPEN admin. 911 called, transp. to ERD, positive wheeze treated and released home.
Client states that within 1.5 hours after vaccine administration, she experienced "hives" described as red blotchy rash on both arms which also began to itch. Went to the infirmary at the facility where vaccines were given and the doctor gave her an antihistamine. States the rash cleared up quickly and had no signs of respiratory distress. TWINRIX was scheduled to be given on 5/3/18 (on accelerated schedule) and this dose was deferred. Instructed pt to consult with her physician if she needs another dose.
I have Distorted taste and smell since receiving the vaccine; I have Distorted taste and smell since receiving the vaccine; This spontaneous case was reported by a consumer and describes the occurrence of TASTE DISORDER (I have Distorted taste and smell since receiving the vaccine) and PAROSMIA (I have Distorted taste and smell since receiving the vaccine) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced TASTE DISORDER (I have Distorted taste and smell since receiving the vaccine) and PAROSMIA (I have Distorted taste and smell since receiving the vaccine). At the time of the report, TASTE DISORDER (I have Distorted taste and smell since receiving the vaccine) and PAROSMIA (I have Distorted taste and smell since receiving the vaccine) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.  Concomitant medication not provided.  Treatment information not provided.
Immediately after the injection, the patient became pale, her lips turned blue and she began gagging (no vomiting). She was made to lay down with her knees elevated and was given a lollipop. She recovered fully within 2 minutes.
fussy & irritable for 3 to 4 days;low grade temp;inconsolably crying for 1 hr periods;small amount of redness & swelling in lt thigh;APAP given q 4hrs;
23 Y/O FEMALE SEEN TODAY FOR HER HEALTH ASSESSMENT AND VACCINATIONS. PATIENT HAS NO PMH AND DENIES TAKING ANY PRESCRIPTION MEDICATIONS.   NKDA  10: 55AM: PATIENT RECEIVED HER TDAP, FLU & VARICELLA VACCIANTIONS TO R ARM WHEN THE PATIENT STARTED TO FEEL UNWELL AND COMPLAINING OF RINGING TO HER RIGHT EAR AFTER COMPLETION OF HER THIRD VACCINATION. 11:00 AM: PATIENT STARTED FELING LIGHTHEADED AND EXHBITING DIAPHORESIS & PALLOR.  FOLLOWED BY NEAR SYNCOPAL EPISODE. PATIENT'S UPPER BODY INCLUDING HER FACE WERE FLUSH/RED. PATIENT HAD ONE EMESIS AND COMPLAINED OF BEING NAUSEATED.  11:05 AM: PATIENTS VITAL SIGNS WERE TAKEN STAT AND B/P: 66/46, P: 54, O2 SAT: 99%, T: 97.4F., R: 14 11:10AM: VS: 88/61/, P: 76, O2 SAT: 99% & R: 14 11:12 AM:ONE DOSE OF DIPHEDYDRAMINE 25MG/IM X 1 DOSE- PER EMERGENCY MEDICAL CARE PROTOCOL 11:15 AM: PATIENT PLACED IN TRENDELENBURG POSITION AND VS REASSESSED: B/P: 98/69, P;76, R: 14 & O2: 100% 11:20AM: MANUAL B/P: 102/80, P: 76, R: 16 11:25AM: PATIENT REPORTED FEELING BETTER, NO RINGING OR PALLOR NOTED IN HER EARS AND WAS A, A, O X 3. PATIENT WAS ABLE TO FOLLOW COMMANDS WITH NO DEFICITS  NOTED. 11:35AM: PATIENT STABLE, VS STABLE AND HUSBAND AT THE PATIENT'S BEDSIDE.  11:45AM: VS: 106/69, 68, 14 & 97.8 F 12:00PM: PATIENT STABLE, SITITNG UP AND STATES SHE FEELS MUCH BETTER.
ADMINISTRATION OF EXPIRED VACCINE; This spontaneous report received from a health care professional concerned a 58 year old male. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included: Patient had no known allergies at the time of vaccination. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 205A21A expiry: 21-SEP-2021) dose was not reported, administered on 12-NOV-2021 for prophylactic vaccination. No concomitant medications were reported.  On 12-NOV-2021, the patient experienced administration of expired vaccine. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of administration of expired vaccine was not reported. This report was non-serious. This case, from the same reporter is linked to 20211129841.
that vaccines cause cancer; sick; Covid virus symptoms; This spontaneous report has been received from a female patient of unknown age via Pfizer referring to herself.  The patient's concurrent condition, medical history and concomitant medication were not provided.    On an unknown date, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) (lot#, expiration date, dose and route were not reported) for prophylaxis.  Other suspect therapies included tetanus vaccine.      On unknown dates,  the patient experienced sick and cancer. The patient also stated that she had 14 coronavirus disease (COVID) symptoms and didn't get tested and went to work. The outcome of the events was unknown. The patient believed that the vaccines made her and her mother (captured in MARRS# 2109USA005477) sick and caused the cancer. The causality of suspected covid-19 was not provided.; Sender's Comments:  US-009507513-2109USA005477:
Low grade fever for 5 days, Headache for 3 days, Fatigue for 5 days, sore arm for 2 days, red, raised area near injection site that felt hot to the touch for 2 days
Muscle pain and tightness at injection site. Not being able to lift arm past shoulder height. Pain with touch or movement of arm. Severe headache, joint pain, generalized body aches, low grade fever, fatigue, chills, nausea and weakness. Called in sick to work. Rest, drinking water, a hot bath, muscle ache cream, alternating Tylenol and Motrin.
Patient admitted with worsening weakness and confusion.  Patient has poor appetite, also.  Patient fell prior to admission.  No hypoxia.
Lumbago, onset 4/11/2021. Still undergoing drug (meloxicam and cyclobenzaprine) and physical therapy as of 6/8/2021. Experiencing some improvement but still have sudden setbacks.
Fever, muscle and bone aches, headache, cough, fatique, diarrhea
soreness at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE PAIN (soreness at the injection site) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025L20A) for COVID-19 vaccination.     No Medical History was provided by the reporter.   On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.   On 15-Jan-2021, the patient experienced INJECTION SITE PAIN (soreness at the injection site).   At the time of the report, INJECTION SITE PAIN (soreness at the injection site) had not resolved.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   Concomitant product use was not provided by the reporter. No treatment information was provided.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded. Further information has been requested
Large red colored rash on right arm, 10 x 5cm. Rash shape is irregular. Rash palpation is elevated.
Red spots around the injection site, hard knot around the injection site and extreme itching for 4-5 days
pt recvd vax 22AUG94 1010AM & 1015 AM pt eye's rolled back & pt fainted & fell to floor; eyes remained closed for approx 2 seconds, skin was cool & clammy, moaning was noted, breathing was sl labored; p100; ambulance called;
Fever; Chills; body aches; nausea; feeling unwell; This is a spontaneous report from a contactable consumer or other non hcp (patient himself). A 49-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number: EN6203, expiration date not reported), via an unspecified route of administration, administered on the left arm on 04Mar2021 12:45 (at the age of 49-years-old), as first dose, single dose for COVID-19 immunization. Medical history included anxiety. Concomitant medication included buspirone (manufacturer unknown) taken for an unspecified indication, start and stop date were not reported. Patient has no reported allergies. Prior to vaccination, the patient was not diagnosed with COVID-19; and since the vaccination, has not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient experienced fever, chills, body aches, nausea, and feeling unwell on 04Mar2021 15:00. Events did not result to physician office visit and emergency room visit. No treatment was given as a result of the events. The outcome of all events reported was not recovered.  No follow-up attempts are possible. No further information is expected.
congestive heart failure; pericarditis; cardiovascular event; balance problems; Zostavax administered to approximately 49-year-old patient; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a currently approximately 57-year-old patient of an unknown gender. No information was provided regarding medical history, concurrent conditions, or concomitant medications. On 16-SEP-2014, the patient was administered the zoster vaccine live (ZOSTAVAX) (dose, route of administration, anatomical location, lot # and expiration date were not specified) at the pharmacy, for the long-term prevention of shingles and zoster-related conditions. Subsequently, on an unknown date, the patient was treated by health care providers for the following injuries resulting from patient's zoster vaccine live (ZOSTAVAX) use: pericarditis, cardiovascular event, congestive heart failure, balance problems. The outcome of the events of pericarditis, cardiovascular event, congestive heart failure and balance problems was not reported. The reporter considered the events to be related to zoster vaccine live (ZOSTAVAX).  Upon internal review, the events of pericarditis and congestive heart failure were determined to be medically significant.
This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 67-year-old female patient who received SHINGRIX for prophylaxis. Previously administered products included SHINGRIX ((refer case US2018205828)). On 9th November 2018, the patient received the 2nd dose of SHINGRIX. On 9th November 2018, less than a day after receiving SHINGRIX, the patient experienced headache. In November 2018, the patient experienced injection site pain, chills and pain. Rechallenge with SHINGRIX was positive. On an unknown date, the outcome of the injection site pain, chills, headache and pain were unknown. It was unknown if the reporter considered the injection site pain, chills, headache and pain to be related to SHINGRIX. Additional details were received as follows: After receiving a dose of SHINGRIX vaccine, the reporter's wife experienced pain at injection site, chills, achiness and headache. The patient planned to follow up with her physician on an unknown date. Follow up information received from consumer on 13th December 2018: The patient did not go to the physician, stayed at home and treated herself.
Post vax, pt began having pain, erythema increasing until 5/10/00 and then began to decrease. Saw pt on 5/11/00. Still had erythema and angioedema from shoulder to elbow with a bruise measuring 2cm X 2cm where IZ given. No fever but did have some chills. Treated with Motrin. The follow up states, "we do not have the requested info as the vaccine was not administered by us. The organization who administered the vaccine is documented on the original form."
A few days after receiving FLUMIST, she developed a cough - occurs during night time, parents have been giving albuterol as needed. Clinic appt pending.
After I tested positive for COVID-19, when I went to give platelets, my Hemoglobin was 12.5 in October. I went to my general physician in early to mid November and had blood work drawn. My A1c was 12.2. I was having slight asthmatic issues. I have the booster shot at the end of November. On December 23, I went in for a pre-op physician and my blood pressure was good. Then in January and February, my blood pressure began to spike and was erratic- 150/70 I had another A1c in February that was 6.8 and another draw in May that was 6.7
Patient reports a large rash around injection site on the morning after the vaccination (11/3/17) and feeling of generalized discomfort. She visited the emergency room on 11/4/17 and was told there was an infection around the injection site. Patient was given antibiotics for treatment (unspecified).
Reacted to 2nd Pfizer short with fever, chills, body aches, nausea, sore throat, blisters and extreme swelling of lips.
Seen in office on 4/30/21 for abdominal pain, question of diverticulitis Hospitalized 5/3 for lower left quadrant pain and groin pain.  Had urine culture and CT abdomen/pelvis.  Admitted for observation, received hydration and medications for pain control.  Discharged next day. Seen by rheumatologist on 5/5/21 for severe left groin pain.  Otherwise her inflammatory arthritis appears to be no worse than before or perhaps slightly better.  Per rheumatologist, he is unsure if the left groin pain is related to rheumatoid arthritis and given the intensity and severity it could be unrelated. Had MRI of hip on 5/6/21 - results were normal Seen at Urgent Care on 5/8 - provider suggested pain could be related to rheumatoid arthritis flare due to COVID vaccination.  Per this provider, there is anecdotal evidence of apparent flares of gout and worsening of chronic autoimmune and rheumatologic conditions. However, that has been more typically in 2-3 time frame from immunization administration.  Patient was cautioned against assigning any definite causation.  Pt's pain has been very thoroughly investigated to date. I have first reassured them that I see no evidence for interim life or limb threatening process. Pain management is complicated by her chronic anticoagulation for afib, and by her reported dizziness with opioids. Although she has good ROM of her left hip without apparent provocation of pain, I still suspect this is primarily an arthritic pain flare. I have politely declined to prescribe any stronger opioid at this point. Pt, spouse, and I have discussed prednisone, with relative contraindication from her xarelto. She is desperate to try something else, and acknowledges increased risk of bleeding with co-administration.    They have asked my experience with post-COVID vaccination syndromes. I have discussed the anecdotal conversations among provider group re: apparent flares of gout and worsening of chronic autoimmune and rheumatologic conditions. However, that has been more typically in 2-3 time frame from immunization administration, and I have cautioned them on assigning any definite causation.
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a female patient of unknown age. No information was provided regarding concomitant medications, concurrent conditions or medical history. In or around 29-SEP-2014, the patient was inoculated with the ZOSTAVAX vaccine at a pharmacy as recommended for routine adult health maintenance for the long term prevention of shingles (dose, route, and lot # not provided).  The vaccine did not prevent shingles as intended and the patient subsequently contracted a persistent strain of herpes zoster. On or about 06-JUN-2014, the patient was treated for a vesicular outbreak, which was diagnosed as shingles. The patient was prescribed acyclovir and MEDROL for management of her painful symptoms and chronic pain. On or about 20-JUN-2016 the patient sought subsequent treatment from the physician for a persistent vesicular rash which was diagnosed as post-herpetic neuralgia, a chronic condition of pain and nerve damage secondary to herpes zoster infections. The patient was prescribed gabapentin for management of her painful symptoms and excruciating pain. As a direct and proximate result of ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. The outcome of the events was unknown. Causality assessment was related. Additional information has been requested.
Information has been received from a pharmacist concerning a 78 year old male patient with a previous cause of shingles in October 2008, who on 16-FEB-2009 was vaccinated with a dose of ZOSTAVAX (Oka/Merck) (lot # 662998/1620X) 0.65ml.  On 18-FEB-2009 the patient experienced a blister above his left eye and itching.  The patient sought advice from his physician who believed that it was a case of shingles. Follow-up information was received on 13-MAY-2009 from the pharmacist via telephone call indicating the patient's name. The pharmacist also reported that he found out later that the patietn had shingles approximately 2 weeks prior to his vaccination, therefore, after the vaccination the shingles re-appeared. The patient was advised to contact a physician. No further information is available.